News
Tokyo, Japan and Cambridge, UK, 8 August 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second ...
Les premiers résultats de l’étude confirmatoire de Phase 3 Denali sur NCX 470 sont attendus entre mi-août et mi-septembre 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results